ADAM17 and rheumatoid arthritis: Indeed, a stable form of the ADAM17 prodomain attenuated ADAM17-mediated disease models of sepsis, rheumatoid arthritis and inflammatory bowel disease via inhibiting TNFα secretion, thus providing in vivo evidence as a potential new highly selective inhibitor of ADAM17 [143].